AB-CHMINACA
Overview[edit | edit source]
AB-CHMINACA is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It is part of a class of compounds that are often used in the production of designer drugs, which are intended to mimic the effects of tetrahydrocannabinol (THC), the active component of cannabis.
Chemical Structure[edit | edit source]
AB-CHMINACA is chemically classified as an indazole-based synthetic cannabinoid. Its structure includes an indazole core, which is a bicyclic compound consisting of a benzene ring fused to a pyrazole ring. The compound is further characterized by the presence of an amide group and a cyclohexylmethyl side chain.
Pharmacology[edit | edit source]
AB-CHMINACA functions as a full agonist at the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system. This system is involved in regulating various physiological processes, including mood, memory, and appetite. The activation of these receptors by AB-CHMINACA can lead to psychoactive effects similar to those produced by THC.
Effects and Risks[edit | edit source]
The use of AB-CHMINACA has been associated with a range of effects, both desired and adverse. Users may experience euphoria, relaxation, and altered perception. However, the compound can also cause severe side effects, such as tachycardia, hypertension, nausea, vomiting, and anxiety. In some cases, the use of AB-CHMINACA has been linked to seizures, psychosis, and even death.
Legal Status[edit | edit source]
Due to its potential for abuse and harmful effects, AB-CHMINACA is classified as a controlled substance in many countries. It is often included in legislation aimed at regulating synthetic cannabinoids and other new psychoactive substances.
Synthesis[edit | edit source]
The synthesis of AB-CHMINACA involves the reaction of an indazole derivative with a cyclohexylmethylamine, followed by the introduction of an amide group. The process requires careful control of reaction conditions to ensure the desired product is obtained.
Related Compounds[edit | edit source]
AB-CHMINACA is structurally related to other synthetic cannabinoids, such as AB-FUBINACA and ADB-CHMINACA. These compounds share similar pharmacological profiles and are often encountered in the context of recreational drug use.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
